FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells

Biochemical Journal

Volumn 452, Issue 1, 2013, Pages 79-86

  Su, Jiechuang ^a   Guise, Christopher P ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Flow cytometry; Fluorogenic probe; Hypoxia; NADPH:cytochrome P450 oxidoreductase; One electron reductase; PR 104A

Indexed keywords

CYTOCHROME P450 REDUCTASE; ELECTRON REDUCTASE; FSL 61; HYDROXYLAMINE; METHIONINE SYNTHASE REDUCTASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE 2A; OXIDOREDUCTASE; QUINOLONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEPENDENT DIFLAVIN OXIDOREDUCTASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; UNCLASSIFIED DRUG;

ARTICLE; CELL HYPOXIA; CELL POPULATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; METABOLITE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL HYPOXIA; FLAVOPROTEINS; FLUORESCENT DYES; HCT116 CELLS; HUMANS; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROQUINOLINES; OXIDOREDUCTASES;

EID: 84876948001     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121695     Document Type: Article

References (40)

1. Jubb, A. M., Buffa, F. M. and Harris, A. L. (2010) Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell. Mol. Med. 14, 18-29
2. Lunt, S. J., Chaudary, N. and Hill, R. P. (2009) The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis 26, 19-34
3. Wilson, W. R. and Hay, M. P. (2011) Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410
4. Chen, Y. and Hu, L. (2009) Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 29, 29-64
5. Tatum, J. L., Kelloff, G. J., Gillies, R. J., Arbeit, J. M., Brown, J. M., Chao, K. S., Chapman, J. D., Eckelman, W. C., Fyles, A. W., Giaccia, A. J. et al. (2006) Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82, 699-757
6. Stratford, M. R., Clarke, E. D., Hodgkiss, R. J., Middleton, R. W. and Wardman, P. (1984) Nitroaryl compounds as potential fluorescent probes for hypoxia. II. Identification and properties of reductive metabolites. Int. J. Radiat. Oncol. Biol. Phys. 10, 1353-1356
7. Thomson, P., Naylor, M. A., Everett, S. A., Statford, M. R. L., Lewis, G., Hill, S., Patel, K. B., Wardman, P. and Davis, P. D. (2006) Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4. Mol. Cancer Ther. 5, 2886-2894
8. Zhu, W., Dai, M., Xu, Y. and Qian, X. (2008) Novel nitroheterocyclic hypoxic markers for solid tumor: synthesis and biological evaluation. Bioorg. Med. Chem. 16, 3255-3260
9. Tanabe, K., Hirata, N., Harada, H., Hiraoka, M. and Nishimoto, S. (2008) Emission under hypoxia: one-electron reduction and fluorescence characteristics of an indolequinone-coumarin conjugate. ChemBioChem 9, 426-432
10. Kiyose, K., Hanaoka, K., Oushiki, D., Nakamura, T., Kajimure, M., Suematsu, M., Nishimatsu, H., Yamane, T., Terai, T., Hirata, Y. and Nagano, T. (2010) Hypoxia-sensitive fluorescent probes for in vivo real-time fluorescence imaging of acute ischemia. J. Am. Chem. Soc. 132, 15846-15848
11. Yin, H., Zhu, W., Xu, Y., Dai, M., Qian, X., Li, Y. and Liu, J. (2011) Novel aliphatic N-oxide of naphthalimides as fluorescent markers for hypoxic cells in solid tumor. Eur. J. Med. Chem. 46, 3030-3037
12. Cui, L., Zhong, Y., Zhu, W., Xu, Y., Du, Q., Wang, X., Qian, X. and Xiao, Y. (2011) A new prodrug-derived ratiometric fluorescent probe for hypoxia: high selectivity of nitroreductase and imaging in tumor cell. Org. Lett. 13, 928-931
13. Rajapakse, A. and Gates, K. S. (2012) Hypoxia-selective, enzymatic conversion of 6-nitroquinoline into a fluorescent helicene: pyrido[3,2-f ]quinolino[6,5-c ]cinnoline 3-oxide. J. Org. Chem. 77, 3531-3537
14. Wardman, P., Clarke, E. D., Hodgkiss, R. J., Middleton, R. W., Parrick, J. and Stratford, M. R. L. (1984) Nitroaryl compounds as potential fluorescent probes for hypoxia. I. Chemical criteria and constraints. Int. J. Radiat. Oncol. Biol. Phys. 10, 1347-1351
15. Patterson, A. V., Ferry, D. M., Edmunds, S. J., Gu, Y., Singleton, R. S., Patel, K., Pullen, S. M., Hicks, K. O., Syddall, S. P., Atwell, G. J. et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-Activated DNA crosslinking agent PR-104. Clin. Cancer Res. 13, 3922-3932
16. Guise, C. P., Abbattista, M. R., Tipparaju, S. R., Lambie, N. K., Su, J., Li, D., Wilson, W. R., Dachs, G. U. and Patterson, A. V. (2012) Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia. Mol. Pharmacol. 81, 31-40
17. Meng, F., Evans, J. W., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J. X., Cai, X., Mowday, A. M., Guise, C. P. et al. (2012) Molecular and cellular pharmacology of the hypoxia-Activated prodrug TH-302. Mol. Cancer Ther. 11, 740-751
18. Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J. X., Ammons, W. S., Curd, J. G., Matteucci, M. D. and Hart, C. P. (2012) Selective tumor hypoxia targeting by hypoxia-Activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin. Cancer Res. 18, 758-770
19. Wang, J., Foehrenbacher, A., Su, J., Patel, R., Hay, M. P., Hicks, K. O. and Wilson, W. R. (2012) The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate bioreductive prodrug CEN-209 under hypoxia. Clin. Cancer Res. 18, 1684-1695
20. Ask, K., Dijols, S., Giroud, C., Casse, L., Frapart, Y. M., Sari, M. A., Kim, K. S., Stuehr, D. J., Mansuy, D., Camus, P. and Boucher, J. L. (2003) Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. Chem. Res. Toxicol. 16, 1547-1554
21. Chandor, A., Dijols, S., Ramassamy, B., Frapart, Y., Mansuy, D., Stuehr, D., Helsby, N. and Boucher, J. L. (2008) Metabolic activation of the antitumor drug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. Chem. Res. Toxicol. 21, 836-843
22. Cenas, N., Prast, S., Nivinskas, H., Sarlauskas, J. and Arner, E. S. (2006) Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J. Biol. Chem. 281, 5593-5603
23. Papadopoulou, M. V., Ji, M., Rao, M. K. and Bloomer, W. D. (2003) Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol. Res. 14, 21-29
24. Wolpert, M. K., Althaus, J. R. and Johns, D. G. (1973) Nitroreductase activity of mammalian liver aldehyde oxidase. J. Pharmacol. Exp. Ther. 185, 202-213
25. Tatsumi, K., Kitamura, S. and Narai, N. (1986) Reductive metabolism of aromatic nitro compounds including carcinogens by rabbit liver preparations. Cancer Res. 46, 1089-1093
26. Adams, P. C. and Rickert, D. E. (1995) Metabolism of [14C]1,3- dinitrobenzene by rat small intestinal mucosa in vitro. Drug Metab. Dispos. 23, 982-987
27. Ueda, O., Kitamura, S., Ohashi, K., Sugihara, K. and Ohta, S. (2003) Xanthine oxidase-catalysed metabolism of 2-nitrofluorene, a carcinogenic air pollutant, in rat skin. Drug Metab. Dispos. 31, 367-372
28. Singleton, D. C. (2009) Antitumour Efficacy of the Nitroreductase-Armed Oncolytic Adenovirus Onyx-411NTR in Combination with Dinitrobenzamide Mustard Prodrugs in Preclinical Models., Ph.D. Thesis, University of Auckland, Auckland, New Zealand
29. Smaill, J. B., Patterson, A. V. and Singleton, D. C. (2010) Method for the fluorescent detection of nitroreductase activity using nitro-substituted aromatic compounds., U.S. Pat. 2010/0173332 A1
30. Guise, C. P., Abbattista, M., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P. et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 70, 1573-1584
31. Jiang, H. B., Ichikawa, M., Furukawa, A., Tomita, S., Ohnishi, T. and Ichikawa, Y. (2001) Metabolic activation of mitomycin C by NADPH-ferredoxin reductase in vitro. Life Sci. 68, 1677-1685
32. Begg, A. C., Hodgkiss, R. J., McNally, N. J., Middleton, R. W., Stratford, M. R. L. and Terry, N. H. A. (1985) Fluorescent markers for hypoxic cells: a comparison of two compounds on three cell lines. Br. J. Radiol. 58, 645-654
33. Hodgkiss, R. J., Begg, A. C., Middleton, R. W., Parrick, J., Stratford, M. R. L., Wardman, P. and Wilson, G. D. (1991) Fluorescent markers for hypoxic cells: a study of novel heterocyclic compounds that undergo bio-reductive binding. Biochem. Pharmacol. 41, 533-541
34. Olive, P. L. (1984) Cellular metabolism of fluorescent nitroheterocycles. Int. J. Radiat. Oncol. Biol. Phys. 10, 1357-1360
35. Olive, P. L. and Chaplin, D. J. (1986) Oxygen and nitroreductase- dependent binding of AF-2 in spheroids and murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 12, 1247-1250
36. Dai, M., Zhu, W., Xu, Y., Qian, X., Liu, Y., Xiao, Y. and You, Y. (2008) Versatile nitro-fluorophore as highly effective sensor for hypoxic tumor cells: design, imaging and evaluation. J. Fluoresc. 18, 591-597
37. Liu, Y., Xu, Y., Qian, X., Liu, J., Shen, L., Li, J. and Zhang, Y. (2006) Novel fluorescent markers for hypoxic cells of naphthalimides with two heterocyclic side chains for bioreductive binding. Bioorg. Med. Chem. 14, 2935-2941
38. Zhu, R., Liu, M. C., Luo, M. Z., Penketh, P. G., Baumann, R. P., Shyam, K. and Sartorelli, A. C. (2011) 4-nitrobenzyloxycarbonyl derivatives of O6-benzylguanine as hypoxia-Activated prodrug inhibitors of O6-Alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine. J. Med. Chem. 54, 7720-7728
39. Penketh, P. G., Shyam, K., Baumann, R. P., Ishiguro, K., Partidge, E. V., Zhu, R. and Sartorelli, A. C. (2012) A strategy for selective O6-Alkylguanine-DNA alkyltransferase depletion under hypoxic conditions. Chem. Biol. Drug Des. 80, 279-290
40. Kurian, J. R., Bajad, S. U., Miller, J. L., Chin, N. A. and Trepanier, L. A. (2004) NADH cytochrome b 5 reductase and cytochrome b 5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J. Pharmacol. Exp. Ther. 311, 1171-1178